SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Innate Pharma SA

Slēgts

1.91 0.53

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.89

Max

1.91

Galvenie mērījumi

By Trading Economics

Ienākumi

57K

-25M

Pārdošana

-8M

4.3M

EPS

-0.3

Peļņas marža

-570.732

Darbinieki

181

EBITDA

2.5M

-23M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

+61.59% upside

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

29M

183M

Iepriekšējā atvēršanas cena

1.38

Iepriekšējā slēgšanas cena

1.91

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Innate Pharma SA Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 6. jūn. 14:31 UTC

Peļņas

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 20:33 UTC

Peļņas

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 19:36 UTC

Tirgus saruna

Oil Futures Post Solid Weekly Gains -- Market Talk

2025. g. 6. jūn. 19:28 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025. g. 6. jūn. 18:46 UTC

Tirgus saruna

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025. g. 6. jūn. 18:02 UTC

Tirgus saruna

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025. g. 6. jūn. 16:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:34 UTC

Peļņas

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025. g. 6. jūn. 16:21 UTC

Tirgus saruna

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 6. jūn. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 6. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 6. jūn. 16:07 UTC

Tirgus saruna

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025. g. 6. jūn. 15:53 UTC

Tirgus saruna

Mexican Inflation Seen Rising in May -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025. g. 6. jūn. 15:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 15:33 UTC

Tirgus saruna

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025. g. 6. jūn. 15:16 UTC

Tirgus saruna

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025. g. 6. jūn. 15:05 UTC

Tirgus saruna

Silver at its Highest In Nearly 15 Years -- Market Talk

2025. g. 6. jūn. 14:35 UTC

Tirgus saruna

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 6. jūn. 14:28 UTC

Tirgus saruna

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025. g. 6. jūn. 14:15 UTC

Tirgus saruna

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025. g. 6. jūn. 14:12 UTC

Peļņas

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025. g. 6. jūn. 14:09 UTC

Peļņas

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Salīdzinājums

Cenas izmaiņa

Innate Pharma SA Prognoze

Cenas mērķis

By TipRanks

61.59% augšup

Prognoze 12 mēnešiem

Vidējais 3.103 EUR  61.59%

Augstākais 3.1 EUR

Zemākais 3.1 EUR

Pamatojoties uz 1 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Innate Pharma SA — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

1 ratings

0

Pirkt

1

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

1.91 / 2.1Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Weak Bullish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Innate Pharma SA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.